Motus GI 

€2.60
0
+€0.00+0% Monday 20:00

Statistics

Day High
2.6
Day Low
2.6
52W High
2.6
52W Low
2.6
Volume
133
Avg. Volume
0
Mkt Cap
15M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

1JanExpected
Q4 0
-1.93
-1.6
-1.27
-0.93
Expected EPS
-1.9349399999999999
Actual EPS
N/A

Financials

-4,027.82%Profit Margin
Unprofitable
2018
2019
2020
2021
2022
2023
294,120.5Revenue
-11.85MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 7M4.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Boston Scientific
BSX
Mkt Cap67.88B
Boston Scientific Corporation offers endoscopy products that compete with Motus GI's Pure-Vu system for colonoscopy preparations.
Medtronic
MDT
Mkt Cap116.77B
Medtronic plc provides a wide range of gastrointestinal products, including devices for endoscopic procedures, directly competing with Motus GI's offerings.
Intuitive Surgical
ISRG
Mkt Cap131.63B
Intuitive Surgical, Inc. specializes in robotic-assisted surgery, including gastrointestinal procedures, offering an alternative to traditional methods supported by Motus GI.
Fresenius Medical Care
FMS
Mkt Cap12.29B
Fresenius Medical Care provides medical devices for dialysis, and their expansion into other medical devices puts them in competition with companies like Motus GI in the broader healthcare market.
Baxter International
BAX
Mkt Cap13.51B
Baxter International Inc. manufactures medical devices and equipment, including products for gastrointestinal treatments, competing with Motus GI.
Stryker
SYK
Mkt Cap126.84B
Stryker Corporation offers medical devices and equipment, including endoscopy products, competing in the same space as Motus GI.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson, through its medical devices segment, offers a range of healthcare products that compete with Motus GI's gastrointestinal solutions.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie Inc., while primarily a pharmaceutical company, has interests in gastrointestinal diseases treatment, indirectly competing with Motus GI through medication that could reduce the need for endoscopic procedures.

About

Motus GI Holdings, Inc. operates as a medical technology company in the United States. It develops Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedures. The company was formerly known as Eight-Ten Merger Corp. and changed its name to Motus GI Holdings, Inc. in November 2016. The company was founded in 2008 and is based in Fort Lauderdale, Florida.
Show more...
CEO
Mark Pomeranz
Employees
15
Country
United States
ISIN
US62014P5044
WKN
000A3EUTL

Listings

0 Comments

Share your thoughts

FAQ

What is Motus GI stock price today?
The current price of 7M4.MU is €2.60 EUR — it has increased by +0% in the past 24 hours. Watch Motus GI stock price performance more closely on the chart.
What is Motus GI stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Motus GI stocks are traded under the ticker 7M4.MU.
Is Motus GI stock price growing?
7M4.MU stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Motus GI has showed a +0% increase.
What is Motus GI market cap?
Today Motus GI has the market capitalization of 15M
What is Motus GI revenue for the last year?
Motus GI revenue for the last year amounts to 294,120.5 EUR.
What is Motus GI net income for the last year?
7M4.MU net income for the last year is -11.85M EUR.
How many employees does Motus GI have?
As of September 05, 2026, the company has 15 employees.
In which sector is Motus GI located?
Motus GI operates in the Health & Wellness sector.
When did Motus GI complete a stock split?
The last stock split for Motus GI was on November 02, 2023 with a ratio of 1:15.
Where is Motus GI headquartered?
Motus GI is headquartered in Fort Lauderdale, United States.